Skip to main content
OpenTrials
Completed

NCT Number: NCT02247752

Follow-up of HBsAg Inactive Carriers Study

The definition of HBs antigen (HBsAg) inactive carrier status has evolved during time. We spoke first from HBsAg" healthy carrier ", then from " asymptomatic carrier ", last from HBsAg" inactive carrier ". This definition continue to be not totally consensual. A very low viral load (< 2000 UI/ml) or undetectable, associated with repetitive normal transaminases and with detectable anti-HBe antibodies were necessary to affirm the inactive carrier status on 2009 EASL recommendations. The 2012 EASL recommendations confirm that the normality of alanine aminotransferase (ALT) with an upper limit of normal (ULN) approximately below 40 UI/ml, like low viral load (HBV-DNA), does necessary be verified every 3 or 4 months during a year to diagnose an inactive carrier. Nevertheless, they admit the possibility for some patients to be inactive carriers with HBV-DNA between 2000 and 20000 UI/ml with consistently normal transaminases This study will follow-up HBsAg inactive carriers during 5 years, in order to evaluate the incidence of unfavourable liver events: chronic hepatits B, liver cirrhosis, hepatocarcinoma (CHC) during this time, and to determine the independant prognosis criteria of unexpected arrival of such events. Secondary outcomes will evaluate HBsAg quantification for the prognosis of such events or, in contrary HBs seroconversion; will evaluate the influence of B genotype on HBsAg level; will evaluate the influence of comorbidities on unexpected arrival of such events.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–70 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Ch General Du Pays D'Aix, Aix-en-Provence, France

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • HBsAg + since one year or more.
  • HBeAg -, anti-HBe antibodies +
  • HBV-DNA < 20000 UI/ml on all dosages realized during past year (ultra-sensitive PCR with a detection threshold < 20 UI/ml), at least 2 dosages during past year.
  • AST and ALT transaminases < ULN on all dosages realized during past year (at least 3).
  • Age > 18 and < 70
  • We will include consecutively all encountered patients (consultation, hospitalization) and diagnosed as HBsAg inactive carriers in each participating center.

Exclusion criteria

  • anti-VHC antibodies +
  • anti-VHD antibodies +
  • anti-VIH antibodies +
  • genetic hemochromatosis
  • liver cirrhosis on liver biopsy or with non-invasive methods (Fibrometer, Fibroscan, Fibrotest, Hepascore …)
  • Past or present treatment against HBV
  • Ultrasonic diagnosis of HCC or Portal Hypertension
  • non compliant patient whom 5 years follow-up seems uncertain.

Treatment and study plan

inactive carrier

Other

Yearly demographic, clinic, biologic and ultrasonic data collection realized during usual follow-up as recommended.

Yearly centralisation of a complementary biological analysis in Paul Brousse Hospital laboratory of virology.

Primary outcomes

  1. Incidence of unfavourable liver events

    Time frame: every year, during 5 years for each

    The primary outcome that the study was designed to evaluate is the incidence of unfavourable liver events (chronic hepatitis B, liver cirrhosis, HCC) in a cohort of patients presumed to be " HBsAg inactive carriers ".

Sponsors and collaborators

Lead sponsor

Centre Hospitalier Régional d'Orléans

Other

Collaborators

  • Faculté de mathématiques ORLEANS
  • INSERM U785-CNR Hôpital Paul Brousse 94800 VILLEJUIF

Registry information

Acronym: PIBAC

Important dates

Study start
2014
Primary completion
2016
Study completion
2022
First posted
Sep 25, 2014
Registry last updated
Apr 6, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.